THERAPEUTIC AREA
saveInfectious Disease
Bacterial, viral, fungal, and parasitic infections.
also known as: id, infection, anti-infective
🐶 often sniffed alongside
top 8- tagRecall67 co-mentions · 51 sources
- tagEndocrinology & Metabolism41 co-mentions · 3 sources
- tagPulmonology21 co-mentions · 20 sources
- tagOncology20 co-mentions · 4 sources
- tagHematology11 co-mentions · 8 sources
- tagCardiology9 co-mentions · 7 sources
- tagDermatology7 co-mentions · 4 sources
- tagVaccine6 co-mentions · 6 sources
drugs
718
catalysts
46
news
719
companies
441
Top drugs
view all →Marketed
CLEOCIN
$PFE · 127 catalysts
Marketedpembrolizumab
Merkel Cell Carcinoma
$MRK · 125 catalysts
MarketedRIFADIN
Tuberculosis
116 catalysts
Marketedclindamycin hydrochloride
Bacterial Pneumonia
90 catalysts
MarketedUNASYN
$PFE · 65 catalysts
Marketedtocilizumab
Coronavirus Disease 2019 (COVID-19)
61 catalysts
MarketedDOXYCYCLINE HYCLATE
$AMRX · 49 catalysts
MarketedMETHYLPREDNISOLONE ACETATE
Giant Cell Arteritis (Temporal Arteritis/Cranial Arteriti…
41 catalysts
🐶 Top companies
view all →Recent catalysts
view all →Apr 30, 2026
phase 2 completion
Instituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)
Vacucis
→
Apr 30, 2026
phase 2 completion
Nanjing First Hospital — amoxicillin (Phase II Trial Completion)
amoxicillin
→
Apr 30, 2026
phase 2 completion
National Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)
metformin hydrochloride ER
→
Apr 30, 2026
phase 2 completion
Qinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)
amoxicillin
→
Apr 30, 2026
phase 1 2 completion
University Hospital Geneva — verteporfin (Phase I/II Trial Completion)
verteporfin
→
Apr 30, 2026
phase 1 initiation
The National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)
DASATINIB
→
Apr 30, 2026
phase 1 initiation
$GILD166.53-1.45%
Gilead Sciences Inc — GS-1701 (Phase I Trial Initiation)
GS-1701
→
Apr 30, 2026
phase 1 completion
Johns Hopkins University — ciprofloxacin (Phase I Trial Completion)
ciprofloxacin
→
Apr 30, 2026
phase 1 completion
MAXVAX Biotechnology Co Ltd — MKK-900 (Phase I Trial Completion)
MKK-900
→
Apr 30, 2026
phase 1 completion
Shenzhen Digestive System Disease Clinical Medicine Research Center — tegoprazan (Phase I Trial Completion)
tegoprazan
→
Recent news
view all →- nChroma halves workforce, BioXcel lets execs gobiospace · 8h ago
- Sanders’ ‘Medicare for All’ plan accrues more liberal and moderate support in Congressstat · 10h ago
- STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatmentstat · 12h ago
- Vaccine biotech Evaxion halts infectious disease, autoimmune work to focus on oncologyfiercebiotech · 13h ago
- nChroma halves headcount, calls time on trial of potential HBV ‘cure’fiercebiotech · 14h ago
- Grand Strand Sandwich Company Recalls Lunch Box Bacon Egg and Cheese Biscuit, Lunch Box Jumbo Sausage Biscuit, Lunch Box Sausage Egg and Cheese Biscuit, Lunch Box Chicken Sausage Biscuit Due to Listeria Monocytogenes Contaminationfda recalls · 18h ago
- What redesigning medical school might look likestat · 1d ago
- Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starnafiercebiotech · 1d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that